Dr Mark Nathan: Medical oncology

Home
Dr Mark Nathan

Fee assured
Verified this account

Overview

Specialises in

Breast

About me

Dr Mark Nathan is a Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust having joined in 2017.
He specialises in treating breast cancer, working at Guys Hospital as well as Kings Hospital and Queen Mary’s Hospital in Sidcup. He is involved in the running of clinical trials at Guys Hospital.
Dr Nathan originates from London and graduated from the Bart’s and the London Medical School in 2006. He undertook his basic training in and around North East London before returning to complete his higher Oncology training at St Bartholomew’s Hospital.
He spent three years obtaining his PhD as an AVON clinical research fellow at the Breakthrough Breast Cancer Research Centre where he also participated in clinics at the Royal Marsden Hospital.

Areas of interest

Breast oncology; Breast cancer; Breast, cancer, chemotherapy; Early and advanced breast cancer treatment; Clinical trials

Medical secretaries

About me

Current NHS consultant posts held

Consultant at Guys Hospital and Kings Hospital London

Research interests

Novel agents in breast cancer

Personal interests

Football, skiing, family

Publications

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. (2016)
Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan MR, Wotherspoon A, Gao Z, Shi Y, Eynden G, Salman A, Lazaris A, Daley F, Gazinska P, Berg T, Eltahir Z, Peckitt C, Ritsma L, Rheenen J, Khashper A, Brown G, Nystrom N, Sund M, Van Laere S, Loyer E, Dirix L, Metrakos P, Cunningham D, Reynolds A.
Nature Medicine: 22: 1294-1302 (2016)

Abstract 4105: Dissecting the mechanisms of hepatocyte replacement in breast cancer liver metastases (2016)
Nathan MR, Kostaras L, Bridgeman VL, Foo S, Vermeulen PB, Reynolds AR
Cancer Research 76 (14 Supplement):4105-4105 · July 2016

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. (2016)
Bridgeman V, Vermeulen P, Foo S, Bilecz A, Kostaras E, Daley F, Nathan MR, Wan E, Frentzas S, SchweigerT, Hegedus B, Vasudev N, Larkin J, Gore M, Dvorak H, Paku S, Kerbel R, Dome B, Reynolds A
The Journal of Pathology: 241(3): 362-374 (2016)

Preclinical evidence that trametinib enhances the response to anti-angiogenic tyrosine kinase inhibitors in renal cell carcinoma. (2015)
Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan P, Larkin J, Gore M, Vasudev NS, Reynolds AR.
Molecular Cancer Therapeutics 15(1):1-12 2015

A review of fulvestrant in breast cancer
Nathan MR, Schmid P
Oncology and Therapy March 2017

The emerging world of breast cancer immunotherapy
Nathan MR, Schmid P
The Breast June 2017

My qualifications & training

My private practice

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

X0003
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 21 days - (5-50)

London Bridge Hospital (5-50)
X0004
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (5-50)

London Bridge Hospital (5-50)
X0002
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 14 days - (1-5)

London Bridge Hospital (1-5)
XR915
Insertion of central venous catheter - tunnelled (x-ray guided) - (1-5)

Report this page Print page

Finder

Note:

Dr Mark Nathan

Medical oncology

Specialises in

About me

Areas of interest

Medical secretaries

Current NHS consultant posts held

Research interests

Personal interests

Publications

Qualifications

GMC registration

Details of entry to specialist register

Practice hours

Practice

Day

Hours

Appt Bookings

Post treatment communication

Information for healthcare professionals (Bupa patients only, last 12 months)